2400 Glycosaminoglycans having an average molecular weight equal to 2400 D suitable for the treatment of senile dementia

摘要

The present invention relates to the preparation of a pharmaceutical composition suitable for the treatment of senile dementia, particularly Alzheimer ' s disease or SDIL (Senile Dementia Alzheimer ' s Type) and cranial nerve damage due to ictus and trauma, The present invention relates to the use of glycosaminoglycan.